Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedside

Area of Science:

• Oncology
• Pharmacology

Background:

• Drug repurposing is a key strategy for novel cancer therapies.
• Alpha-1 adrenoreceptor blockers are established treatments for hypertension and benign prostatic hyperplasia.
• Quinazoline derivatives within this class exhibit cytotoxic effects.

Purpose of the Study:

• To review evidence on the anti-cancer properties of alpha-1 adrenoreceptor blockers.
• To investigate the mechanisms underlying their cytotoxic effects.
• To assess the potential clinical application of these agents in cancer therapy.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of cytotoxic and anti-cancer mechanisms.
• Evaluation of drug repurposing potential.

Main Results:

• Certain alpha-1 blockers, particularly quinazoline derivatives, demonstrate significant cytotoxic activity against cancer cells.
• Mechanisms include induction of apoptosis and inhibition of cell proliferation.
• Evidence suggests potential therapeutic benefits in various cancer types.

Conclusions:

• Alpha-1 adrenoreceptor blockers represent a promising avenue for cancer drug repurposing.
• Further research is warranted to translate these findings into clinical cancer treatments.